ProCE Banner Activity

How I Am Using HD IL-2 in My Practice Today

Clinical Thought
Despite the advance of newer immunotherapies and targeted agents for the treatment of RCC, high-dose IL-2 has an important role in achieving a durable response. Read my thoughts on when to consider it and which patients may benefit the most.

Released: August 24, 2020

Expiration: August 23, 2021

No longer available for credit.

Share

Faculty

Brendan D. Curti

Brendan D. Curti, MD

Robert W. Franz Endowed Chair for Clinical Research
Earle A. Chiles Research Institute
Providence Cancer Institute
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Clinigen Inc

Faculty Disclosure

Primary Author

Brendan D. Curti, MD

Robert W. Franz Endowed Chair for Clinical Research
Earle A. Chiles Research Institute
Providence Cancer Institute
Portland, Oregon

Brendan D. Curti, MD, has disclosed the he has received funds for research support from AstraZeneca, Clinigen, and Galectin and consulting fees from Clinigen and Merck.